Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations

Journal of Clinical Microbiology

Volumn 38, Issue 4, 2000, Pages 1563-1568

  Pelletier, René ^a   Peter, Joanne ^a   Antin, Cynthia ^a   Gonzalez, Corina ^a   Wood, Lauren ^a   Walsh, Thomas J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Pediatric Oncology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CROSS RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; THRUSH;

CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034003933     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.4.1563-1568.2000     Document Type: Article

References (31)

1. Barchiesi, F., A. Giacometti, D. Arzeni, P. Branchesi, G. Crescenzi, F. Ancarani, and G. Scalise. 1992. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. J. Chemother. 4:381-386.
2. Bart, D. E., P. Boiron, A. Carlotti, and B. Dupont. 1993. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J. Clin. Microbiol. 31:2933-2937.
3. Bergan, T., and M. Vangdal. 1983. In vitro activity of antifungal agents against yeast species. Chemotherapy 29:104-110.
4. Hamilton, M. J. 1972. A comparative in vitro study of amphotericin B, clotrimazole and 5-fluorocytosine against clinically isolated yeasts. Sabouraudia 10:276-83.
5. Hoeprich, P. D., and A. C. Huston. 1976. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J. Infect. Dis, 134:336-41.
6. Hoeprich, P. D., and A. C. Huston. 1975. Susceptibility of Cocddioides immitis. Candida albicans, and Cryptococcus neoformans to amphotericin B and clotrimazole. J. Infect. Dis. 132:133-141.
7. Holt, R. J. 1974. Laboratory and clinical studies with clotrimazole. Postgrad. Med. J. 1:24-26.
8. Holt, R. J. 1972. Laboratory assessment of the antimycotic drug clotrimazole. J. Clin. Pathol. 25:1089-1097.
9. Holt, R. J., and A. Azmi. 1978. Miconazole-resistant Candida. Lancet i:50-51.
10. Hussain, Q. S., D. J. Flournoy, S. G. Qadri, and E. G. Ramirez. 1986. Susceptibility of clinical isolates of yeasts to anti-fungal agents. Mycopathologia 95:183-187.
11. Ipp, M. M., L. Boxall, and E. W. Gelfand. 1977. Clotrimazole: intermittent therapy in chronic mucocutaneous candidiasis. Am. J. Dis. Child. 131:305-307.
12. Leikin, S., R. Parrott, and J. Randolph. 1976. Clotrimazole treatment of chronic mucocutaneous candidiasis. J. Pediatr. 88:864-866.
13. Lucatorto, F. M., C. Franker, W. D. Hardy, and S. Chafey. 1991. Treatment of refractory oral candidiasis with fluconazole: a case report. Oral Surg. Oral Med. Oral Pathol. 71:42-44.
14. Millon, L., A. Manteaux, G. Reboux, C. Drobacheff, M. Monod, T. Barale, and B. Y. Michel. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1115-1118.
15. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Pfaller, M. A., and T. Gerarden. 1989. Susceptibility of clinical isolates of Candida spp. to terconazole and other azole antifungal agents. Diagn. Microbiol. Infect. Dis. 12:467-471.
17. Phair, J. P., A. Munoz, R. Detels, et al. 1990. The risk of Pneumoeystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N. Engl. J. Med. 322:161-165.
18. Plempel, M. 1982. On the action kinetics of clotrimazole. Chemotherapy 1:22-31.
19. Plempel, M., K. Bartmann, K. H. Büchel, and E. Regel. 1969. BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity. Antimicroh. Agents Chemother. 9:271-274.
20. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghanuoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
21. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
22. Rothenberg, R., M. Woelfel, R. Stoneburner, et al. 1987. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N. Engl. J. Med. 317:1297-1302.
23. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kaubnan. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
24. Saubolle, M. A., and P. D. Hoeprich. 1978. Disk agar diffusion susceptibility testing of yeasts. Antimicrob. Agents Chemother. 14:517-530.
25. Shadorav, S. 1971. In vitro antifungal activity of dotrimazole (Bay b 5097). Infect. Immun. 4:143-148.
26. Shadomy, S., D. M. Dixon, and R. May. 1982. A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia 20:313-323.
27. Torres-Rodríguez, J. M., R. Mendez, O. López-Jodra, Y. Morera, M. Espasa, T. Jimenez, and C. Lagunas. 1999. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob. Agents Chemother. 43: 1258-1259.
28. U.S. Pharmacopoeia. 1995. USP D1 vol. 1; drug information for the health care professional, 1995 edition, p. 798. U.S. Pharmacopeia, Rockville, Md.
29. van Belkum, A., W. Melchers, P. B. de, S. Scherer, W. Quint, and J. F. Meis. 1994. Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J. Infect. Dis. 169:1062-1070.
30. Warren, N. G., and K. C. Hazen. 1999. Candida, Cryptococcus, and other yeasts of medical importance, p. 1184-1199. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
31. White, T. C., M. A. Pfaller, M. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1):S102-S109.